KAINOS Laboratories,Inc. Board Supports

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 6, 2026. It represents a primary source document for Japanese M&A sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

KAINOS Laboratories,Inc. Board Supports Tender Offer, Recommends Shareholders Tender

Source disclosure: February 06, 2026 KAINOS Laboratories,Inc. [4556.T] TOKYO — Kainos Laboratories, Inc., represented by President and CEO Etsu Hirohiro (stock code 4556 on the Tokyo Stock Exchange Standard), announced today that its board of directors has revised the company's fiscal year 2026 March-end dividend forecast to zero, contingent upon the successful tender offer made by Flowers Corporation. The decision was disclosed following a board meeting held on February 6, 2026. Th